Skip to main content

Table 2 Comparison of patients in the treatment-naïve and pre-treated groups who were treated with a fixed-dosing intravitreal aflibercept regimen

From: One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

  Treatment-naïve case (n=12) Pre-treated (n=13) P-value
(Treatment-naïve vs. Pre-treated)
Baseline 12 months Δ and P-value Baseline 12 months Δ and P-value
BCVA at 12 months from baseline
(ETDRS letters)
66.58±14.79 76.36±6.59 Δ =9.78 letters
p= 0.005a
64.46±16.52 64.46±14.61 Δ = 0 letters
p= 1.000a
0.004b
Retinal thickness at 12 months from baseline (um) 462±160 243.55±162 Δ = 218.45
p= 0.000a
356.08±145 303.69±139 Δ = 52.39
p= 0.23a
0.009b
Number and Proportion of patients with complete polyp regression at month 12 n (%)   5 (41.6%)    5 (38.4%)   0.87c
Number and Proportion of patients with dry retina at month 12 n (%)   8 (67%)    7 (53.8%)   0.51c
  1. a Paired T-test b T-test c Chi-squared test)
\